News Quantified

CRDL – cardiol therapeutics inc. - class a common shares (US:NASDAQ)

Cardiol Therapeutics Inc. (NASDAQ: CRDL) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $9.00 price target on the stock.

5/14

07:30 am

crdl

Low

Cardiol Therapeutics Announces Phase II ARCHER Trial Presented at the World Congress on Acute Heart Failure 2024 [Yahoo! Finance]

Cardiol Therapeutics Inc. (NASDAQ: CRDL) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $9.00 price target on the stock.

Cardiol Therapeutics Announces Year-End 2023 Update on Operations [Yahoo! Finance]

Cardiol Therapeutics Completes Patient Enrollment in its Phase II MAvERIC-Pilot Study Investigating CardiolRx(TM) for Recurrent Pericarditis [Yahoo! Finance]

Live Event: Join our next subscriber-only event: "The Data Driven Investor"

Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

52 Week High	{{GetCompanyStockInfo.Week52HighValue}} {{GetCompanyStockInfo.Week52HighDate}}
52 Week Low	{{GetCompanyStockInfo.Week52LowValue}} {{GetCompanyStockInfo.Week52LowDate}}

Today’s Volatility	{{VolatilityStr}}
20 Day Volatility	{{Volatility20Str}}

Open	{{GetCompanyStockInfo.Open}}
Prior Close	{{GetCompanyStockInfo.PriorCloseValue}} {{GetCompanyStockInfo.PriorCloseDate}}